Edge Therapeutics (EDGE) Stock Price, News & Analysis

Company Overview

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Key Stats

• Today's Range: $40.19 to $40.30
• 50-Day Range: $0.50 to $6.71
• 52-Week Range: $0.28 to $17.38
• Volume: 151 shs
• Average Volume: 373,201 shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EDGE Stock Analysis - Frequently Asked Questions

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics, Inc. (NASDAQ:EDGE) issued its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.16.

What other stocks do shareholders of Edge Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Bristol Myers Squibb (BMY), Cerecor (CERC) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 11/01/2018
• Today: 7/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EDGE
• CIK: 1472091
• Web: www.edgetherapeutics.com
• Phone: (800) 208-3343
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.29%
• Return on Assets: -56.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.59
• Quick Ratio: 5.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.95 per share
• Price / Book: 42.42

Miscellaneous

• Outstanding Shares: 31,510,000
• Free Float: N/A
• Market Cap: $1.27 billion
• Optionable: Not Optionable
• Beta: 3.65